PMx modeling

I specialize in population pharmacokinetics (PK), pharmacokinetic-pharmacodynamic (PKPD) modeling, and exposure-response (ER) analysis. My expertise enables me to develop population models that provide crucial insights for both internal and regulatory decision-making, delivered in time. For example, I can help you identify factors contributing to variability in your drug’s performance.

Additionally, I can determine whether dose adjustments are necessary based on patient characteristics such as body weight, age, sex, and race, as well as considerations for vulnerable populations like those with liver or renal impairment, or those taking concomitantmedications. I also clarify the relationship between drug exposure and its efficacy, safety, and relevant biomarkers.

Below you find keywords related to some of my pharmacometric analyses expertise